View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsLa Jolla Pharmaceutical 향후 성장Future 기준 점검 4/6La Jolla Pharmaceutical은 연간 수입과 매출이 각각 59%와 19.8% 증가할 것으로 예상되고 EPS는 연간 55.8%만큼 증가할 것으로 예상됩니다.핵심 정보59.0%이익 성장률55.82%EPS 성장률Biotechs 이익 성장25.2%매출 성장률19.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Major Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.분석 기사 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...모든 업데이트 보기Recent updatesMajor Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.Reported Earnings • Aug 16Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021)Second quarter 2022 results: EPS: US$0.097 (down from US$0.14 in 2Q 2021). Revenue: US$10.5m (down 34% from 2Q 2021). Net income: US$2.46m (down 34% from 2Q 2021). Profit margin: 23% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 20%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 97% share price gain to US$6.14, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 10x in the Biotechs industry in the US. Total loss to shareholders of 34% over the past three years.Seeking Alpha • Jul 11Innoviva to acquire La Jolla Pharma for $149M including debtInnoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday. Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset. The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP). Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days. In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections. The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 9x in the Biotechs industry in the US. Total loss to shareholders of 64% over the past three years.Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0 (down from US$0.53 in 1Q 2021). Revenue: US$10.4m (down 70% from 1Q 2021). Net income: US$2.0k (down 100% from 1Q 2021). Profit margin: 0% (down from 42% in 1Q 2021). Revenue missed analyst estimates by 20%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 36% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: US$0.72 (up from US$1.44 loss in FY 2020). Revenue: US$75.7m (up 127% from FY 2020). Net income: US$19.7m (up US$59.1m from FY 2020). Profit margin: 26% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Products in clinical trials Phase III: 1 Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 26% compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Dec 08Independent Director recently bought US$92k worth of stockOn the 6th of December, David Ramsay bought around 25k shares on-market at roughly US$3.75 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$194k more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$4.85, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 70% over the past three years.분석 기사 • Nov 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) strong earnings didn't...Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$13.3m (up 47% from 3Q 2020). Net loss: US$2.26m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$4.30, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 82% over the past three years.Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$4.18, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 80% over the past three years.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.57 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$16.1m (up 177% from 2Q 2020). Net income: US$3.73m (up US$19.3m from 2Q 2020). Profit margin: 23% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.Seeking Alpha • Jul 02Our Take On La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring. With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive. A full investment analysis follows in the paragraphs below.Recent Insider Transactions • May 27Independent Director recently bought US$70k worth of stockOn the 24th of May, David Ramsay bought around 20k shares on-market at roughly US$3.49 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$261k more in shares than they have sold in the last 12 months.Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.53 (vs US$0.32 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$34.1m (up 350% from 1Q 2020). Net income: US$14.4m (up US$23.0m from 1Q 2020). Profit margin: 42% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.분석 기사 • Mar 11La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the La Jolla Pharmaceutical Company...Reported Earnings • Mar 10Full year 2020 earnings released: US$1.44 loss per share (vs US$4.30 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$33.4m (up 45% from FY 2019). Net loss: US$39.4m (loss narrowed 66% from FY 2019). Products in clinical trials Phase III: 1 Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 10Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 107%, compared to a 1,438% growth forecast for the Biotechs industry in the US.분석 기사 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...Is New 90 Day High Low • Feb 05New 90-day high: US$7.33The company is up 105% from its price of US$3.57 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$45.64 per share.Price Target Changed • Jan 27Price target raised to US$11.94Up from US$10.67, the current price target is an average from 3 analysts. The new target price is 85% above the current share price of US$6.46. As of last close, the stock is down 7.4% over the past year.분석 기사 • Jan 16Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%Celebrations may be in order for La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders, with the analysts...Is New 90 Day High Low • Jan 13New 90-day high: US$5.04The company is up 22% from its price of US$4.14 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$37.00 per share.분석 기사 • Jan 05Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...분석 기사 • Dec 09Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Generally...Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 78%, compared to a 372% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$9.07m (up 59% from 3Q 2019). Net loss: US$11.8m (loss narrowed 60% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 30New 90-day low: US$3.40The company is down 15% from its price of US$3.98 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$47.33 per share.이익 및 매출 성장 예측NasdaqCM:LJPC - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20247716N/AN/A112/31/2023648N/AN/A112/31/2022471N/AN/A16/30/20224641313N/A3/31/20225251414N/A12/31/202176202828N/A9/30/202174121818N/A6/30/202170377N/A3/31/202160-16-8-8N/A12/31/202033-39-38-38N/A9/30/202030-61-48-47N/A6/30/202026-79-57-56N/A3/31/202026-93-65-65N/A12/31/201923-117-86-85N/A9/30/201920-137-101-100N/A6/30/201918-158-119-118N/A3/31/201914-181-141-139N/A12/31/201810-199-155-152N/A9/30/20186-193-153-146N/A6/30/20182-168-136-127N/A3/31/20181-142-118-109N/A12/31/2017N/A-115-94-85N/A9/30/20170-101-83-78N/A6/30/20170-96-78-75N/A3/31/20170-85-70-68N/A12/31/20161-78-61-59N/A9/30/20161-65-50-49N/A6/30/20162-54-40-39N/A3/31/20161-49N/A-33N/A12/31/20151-42N/A-25N/A9/30/20151-37N/A-22N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: LJPC 의 연간 예상 수익 증가율(59%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: LJPC 의 연간 수익(59%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: LJPC 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: LJPC 의 수익(연간 19.8%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: LJPC 의 수익(연간 19.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: LJPC의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/08/22 19:52종가2022/08/19 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스La Jolla Pharmaceutical Company는 11명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Keay NakaeChardan Capital Markets, LLCReni BenjaminH.C. Wainwright & Co.Eun Kyung YangJefferies LLC8명의 분석가 더 보기
Major Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.
Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.
Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.
Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.
Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.
분석 기사 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...
Major Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.
Reported Earnings • Aug 16Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021)Second quarter 2022 results: EPS: US$0.097 (down from US$0.14 in 2Q 2021). Revenue: US$10.5m (down 34% from 2Q 2021). Net income: US$2.46m (down 34% from 2Q 2021). Profit margin: 23% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 20%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 97% share price gain to US$6.14, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 10x in the Biotechs industry in the US. Total loss to shareholders of 34% over the past three years.
Seeking Alpha • Jul 11Innoviva to acquire La Jolla Pharma for $149M including debtInnoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday. Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset. The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP). Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days. In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections. The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 9x in the Biotechs industry in the US. Total loss to shareholders of 64% over the past three years.
Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.
Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0 (down from US$0.53 in 1Q 2021). Revenue: US$10.4m (down 70% from 1Q 2021). Net income: US$2.0k (down 100% from 1Q 2021). Profit margin: 0% (down from 42% in 1Q 2021). Revenue missed analyst estimates by 20%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 36% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.
Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.
Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: US$0.72 (up from US$1.44 loss in FY 2020). Revenue: US$75.7m (up 127% from FY 2020). Net income: US$19.7m (up US$59.1m from FY 2020). Profit margin: 26% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Products in clinical trials Phase III: 1 Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 26% compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Dec 08Independent Director recently bought US$92k worth of stockOn the 6th of December, David Ramsay bought around 25k shares on-market at roughly US$3.75 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$194k more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$4.85, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 70% over the past three years.
분석 기사 • Nov 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) strong earnings didn't...
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$13.3m (up 47% from 3Q 2020). Net loss: US$2.26m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$4.30, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 82% over the past three years.
Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$4.18, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 80% over the past three years.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.57 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$16.1m (up 177% from 2Q 2020). Net income: US$3.73m (up US$19.3m from 2Q 2020). Profit margin: 23% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.
Seeking Alpha • Jul 02Our Take On La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring. With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive. A full investment analysis follows in the paragraphs below.
Recent Insider Transactions • May 27Independent Director recently bought US$70k worth of stockOn the 24th of May, David Ramsay bought around 20k shares on-market at roughly US$3.49 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$261k more in shares than they have sold in the last 12 months.
Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.53 (vs US$0.32 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$34.1m (up 350% from 1Q 2020). Net income: US$14.4m (up US$23.0m from 1Q 2020). Profit margin: 42% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 11La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the La Jolla Pharmaceutical Company...
Reported Earnings • Mar 10Full year 2020 earnings released: US$1.44 loss per share (vs US$4.30 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$33.4m (up 45% from FY 2019). Net loss: US$39.4m (loss narrowed 66% from FY 2019). Products in clinical trials Phase III: 1 Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 10Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 107%, compared to a 1,438% growth forecast for the Biotechs industry in the US.
분석 기사 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...
Is New 90 Day High Low • Feb 05New 90-day high: US$7.33The company is up 105% from its price of US$3.57 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$45.64 per share.
Price Target Changed • Jan 27Price target raised to US$11.94Up from US$10.67, the current price target is an average from 3 analysts. The new target price is 85% above the current share price of US$6.46. As of last close, the stock is down 7.4% over the past year.
분석 기사 • Jan 16Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%Celebrations may be in order for La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders, with the analysts...
Is New 90 Day High Low • Jan 13New 90-day high: US$5.04The company is up 22% from its price of US$4.14 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$37.00 per share.
분석 기사 • Jan 05Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
분석 기사 • Dec 09Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Generally...
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 78%, compared to a 372% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$9.07m (up 59% from 3Q 2019). Net loss: US$11.8m (loss narrowed 60% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 30New 90-day low: US$3.40The company is down 15% from its price of US$3.98 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$47.33 per share.